Effect of intermittent PTH administration in the periodontitis-associated bone loss in ovariectomized rats

Marques, Marcelo Rocha; Silva, Marco Antonio Dias da; Manzi, Flávio Ricardo; Neto, João Batista César; Nociti, Francisco Humberto; Barros, Silvana P.

doi:10.1016/j.archoralbio.2004.08.014

Cited by 53 publications

(51 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Recent studies have indicated that intermittent doses of PTH can be an efficient anabolic treatment, reducing bone loss due to estrogendeficiency-related osteopenia. 111 Furthermore, daily injections of teriparatide, a portion of human PTH, have been shown to stimulate new bone formation and increase BMD. 112 Of note, NO has anabolic and catabolic effects similar to those of PTH on bone metabolism.…”

Section: Periodontal Disease and Osteoporosismentioning

confidence: 99%

Periodontal disease and systemic conditions: a bidirectional relationship

2006

View full text Add to dashboard Cite

For decades, physicians and dentists have paid close attention to their own respective fields, specializing in medicine pertaining to the body and the oral cavity, respectively. However, recent findings have strongly suggested that oral health may be indicative of systemic health. Currently, this gap between allopathic medicine and dental medicine is quickly closing, due to significant findings supporting the association between periodontal disease and systemic conditions such as cardiovascular disease, type 2 diabetes mellitus, adverse pregnancy outcomes, and osteoporosis. Significant effort has brought numerous advances in revealing the etiological and pathological links between this chronic inflammatory dental disease and these other conditions. Therefore, there is reason to hope that the strong evidence from these studies may guide researchers towards greatly improved treatment of periodontal infection that would also ameliorate these systemic illnesses. Hence, researchers must continue not only to uncover more information about the correlations between periodontal and systemic diseases but also to focus on positive associations that may result from treating periodontal disease as a means of ameliorating systemic diseases.

show abstract

Section: Periodontal Disease and Osteoporosismentioning

confidence: 99%

Periodontal disease and systemic conditions: a bidirectional relationship

2006

View full text Add to dashboard Cite

show abstract

“…In vitro and depending on cell state, teriparatide influences PDL cell survival and causes osteoblast-like behavior with increased osteoprotegerin expression [123, 124]. It has been tested in rats with induced osteoporosis, where it caused increased bone mineralization and formation in extraction sockets and prevented periodontal bone loss [125, 126]. In canine GBR, teriparatide improved bone formation around implants [127, 128].…”

Section: Growth Factors and Protein Deliverymentioning

confidence: 99%

Tissue engineering for bone regeneration and osseointegration in the oral cavity

et al. 2015

View full text Add to dashboard Cite

“…Animal studies have also demonstrated that the anabolic agent PTH (1-34) could be potentially useful to preserve periodontal bone mass [247][248] (Table 5). Other reports have shown that inhibition of different cellular and molecular steps of the inflammatory response to the oral bacteria or blockade of RANKL actions, may be beneficial to inhibit periodontal bone loss in animal models ( Table 5, Fig.…”

Section: Investigational Agents and Preclinical Resultsmentioning

confidence: 96%

Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio

Valverde¹

2008

CMC

View full text Add to dashboard Cite

In this review, benefits and side-effects of current and emerging therapies to treat and prevent pathological bone loss are described. Bisphosphonates are the antiresorptive compounds most widely used in the treatment of bone-loss associated diseases. They are generally well-tolerated although have recently been associated with osteonecrosis of the jaw and other complications. Therapies modulating estrogen receptor activation are indicated in the prevention and treatment of either breast cancer or osteoporosis in postmenopausal women. Thus, hormone replacement therapy is effective in prevention of osteoporosis, but its long-term use can increase the risk of breast cancer, stroke and embolism. Tamoxifen benefits all stages of breast cancer, but its use may lead to uterine cancer and thromboembolism. Raloxifene is approved in prevention of breast cancer and treatment of postmenopausal osteoporosis, but its use can increase the risk of fatal stroke. Aromatase inhibitors are superior to tamoxifen at advanced stages of disease and as adjuvants, but their use increase fracture incidence. Fulvestrant is as effective as aromatase inhibitors in the treatment of advanced breast cancer and does not cause bone fractures. Another antiresorptive available for the treatment of postmenopausal osteoporosis, Paget's disease and hypercalcemia is calcitonin, which also exhibits analgesic effects. A promising antiresorptive agent currently in clinical trials is denosumab. Aditional therapies for osteoporosis that decrease fracture risk consist of PTH-like anabolic agents and the dual action bone agent strontium ranelate. Antiseptics and antibiotics are used extensively in periodontal disease intervention to target bacterial biofilm, although host-directed therapies are also being developed.

show abstract

Effect of intermittent PTH administration in the periodontitis-associated bone loss in ovariectomized rats

Cited by 53 publications

References 32 publications

Periodontal disease and systemic conditions: a bidirectional relationship

Periodontal disease and systemic conditions: a bidirectional relationship

Tissue engineering for bone regeneration and osseointegration in the oral cavity

Pharmacotherapies to Manage Bone Loss-Associated Diseases: A Quest for the Perfect Benefit-to-Risk Ratio

Contact Info

Product

Resources

About